ArticleBMC research notes2025
IgG antibodies anti-LcrV of Yersinia pestis: inconsistent responses in confirmed plague patients from Madagascar.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolutionary trends of plague research from 2016 to 2025: A bibliometric analysis.PLoS neglected tropical diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivePlague (Yersinia pestis infection) is a flea-borne zoonotic disease mainly affecting African countries, with most human cases reported from Madagascar and the Democratic Republic of Congo. Although curable, plague can be fatal without prompt treatment, highlighting the importance of reliable diagnostics. Current tests include bacteriological culture, PCR, and anti-F1 ELISA, however the anti-F1 serology has limitations due to the existence of F1-negative virulent strains. To address this, we developed a serological test detecting IgG antibodies against LcrV or V antigen, the main virulence factor of Y. pestis and further evaluated the developed test on clinical samples.
resultsV antigen was produced from the culture of V-pGEX-6P-2 clones and purified as GST-LcrV, which was functional for ELISA plate coating. The developed anti-V ELISA showed 60% sensitivity and 93.3% specificity when tested on confirmed plague patients’ serum samples from Madagascar. However, evaluation on convalescent sera collected from Day 1 to Month 3 post-infection revealed inconsistent anti-V antibody production. This suggests the anti-V ELISA is best used as a complementary test for plague diagnosis and during outbreak investigations. In addition, this study provides valuable insight into the humoral response diversity following Y. pestis infection, representing crucial information for plague vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.